Skip to content

Released Nov 13, 2025, before the open

10-Q filed Nov 13, 2025, 44 days after period end · 0001193125-25-279096

Q3 2025 · 10-Q
Revenue$1.74M−43.4% vs Q3 2024−8.7% vs Q2 2025
Net Income-$32.25MN/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.27N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$34,735,000N/M
Operating Cash Flowderived-$24,374,000N/M
Free Cash Flowderived-$26,577,000N/M
Margins · derived
Operating margin-1995.1%−291.2 pt vs Q3 2024
Net margin-1852.4%−301.4 pt vs Q3 2024

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023Q3 2022
Revenue$1.74M$3.07M$1.94M$14.98M
Net Income-$32.25M-$47.68M-$45.17M-$83.56M
EPS Diluted-$0.27-$0.40-$0.46-$0.86

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR